[Clinical evaluation of SM-4300, a new human immunoglobulin preparation].
Clinical efficacy and safety of SM-4300, a newly developed human immunoglobulin preparation for intravenous use, were evaluated in 11 patients with severe infectious disease which are resistant to antibiotic therapy in the combined use with the antibiotics. Clinical effects of SM-4300 wee excellent in 1 case, good in 5 cases, fair in 1 case, poor in 1 case and unevaluable in 3 cases. The efficacy rate was summarized as 75%. Bacteriological responses were eradicated in 1 case and unknown in 10 cases. No side effects and abnormal laboratory findings due to SM-4300 were observed in this investigation.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000628:therapy*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000628:therapy; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000628:therapy; D014552:Urinary Tract Infections / Q000628:therapy
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300